Abstract
Patients with schizophrenia frequently develop drug-induced hyperprolactinaemia and consequent hypogonadism. Reduced bone mineral density as a consequence of hyperprolactinaemia-induced hypogonadism has been well documented in medical, but not psychiatric, disorders. Little attention has been given to the potential risk of developing osteoporosis secondary to anti-psychotic-induced hyperprolactinaemia. Three cases are presented that illustrate how this debilitating but silent disease may affect even those young individuals with schizophrenia.
Get full access to this article
View all access options for this article.
